Answers are grounded in this paper and cite their sources.
(1) Currently, the survival prognosis for patients with relapsed and refractory acute myeloid leukemia (R/R AML) is extremely poor. Therefore, the exploration of novel drugs is imperative to enhance the prognosis of patients with R/R AML. The therapeutic efficacy and mechanism of Chidamide, a novel epigenetic regulatory drug, in the treatment of R/R AML remain unclear.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: